Devices · Anumana, Inc.

ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040)

Anumana, Inc. is listed for ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm (1040) (K253801). The FDA list gives April 7, 2026 as the date of the final decision. The lead panel is Cardiovascular, and the database link on the FDA list is the 510(k) pathway. openFDA describes product code SHP as “Cardiac Amyloidosis Machine Learning-Based Notification Software”: Cardiac Amyloidosis machine learning-based notification software employs machine learning techniques to suggest the likelihood of cardiac amyloidosis for further referral or diagnostic follow-up. openFDA records this submission’s decision description as “Substantially Equivalent.” This paragraph is assembled only from those public fields. It is not an FDA review, not a determination of safety or effectiveness, and not medical advice. Official record: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K253801

Official FDA database record

Date of final decision

April 7, 2026

Company on the FDA list

Anumana, Inc.

Lead panel

Cardiovascular

Primary product code

SHP

openFDA device name for the code

Cardiac Amyloidosis Machine Learning-Based Notification Software

Device class

2

Regulation number

870.2380

openFDA decision description

Substantially Equivalent

openFDA decision code

SESE

Statement or summary label

Summary